Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.

Front Oncol · 2023 · PMC10020225 · PMID 36937443

Europe PMC DOI

hedged sentence

0.2620

closest p · 5.2× alpha

0.2620

boldest claim

The sentences

an increasing trendp=0.262not close (p > 0.1)

Although the PFS in the RP group showed an increasing trend compared with that in the regorafenib monotherapy group, there was no statistical significance (3.8 vs 2.4 months, p=0.262 Figure 3G ).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.